Facebook is changing up its News Feed, a new twist in the "All the Money in the World" wage gap controversy, and Lindsay Lohan might design a manmade island in Dubai. Plus, wrapping up the biggest headlines from CES with Wired, celebrity fashion designer Isaac Mizrahi, and the star of Amazon's "Philip K. Dick's Electric Dreams." Plus, why YouTube took two weeks to punish Logan Paul after posting a video of an apparent suicide victim. We also break down Nintendo's surprise announcement of new games coming to Switch in 2018. Marvel's television future is in question after an ABC executive suggested "Inhumans" is due for cancellation. We speak with Vogue.com about E!'s future in the Time's Up era. Then, it's Your Future Home brought to you by Rocket Mortgage by Quicken Loans. We discuss your future robot realtor and how to win in a bidding war.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More